Immunotherapy plus chemotherapy before surgery for early triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy, before surgery, can improve treatment for early triple-negative breast cancer. It compares two chemotherapy approaches—one with anthracyclines and one without—to see which works better when combined with toripalimab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your breast cancer is confirmed as triple-negative (negative for estrogen, progesterone, and HER2 receptors).
- The cancer is in the breast and possibly nearby lymph nodes, but has not spread to distant organs.
- You have not had chemotherapy, hormone therapy, targeted therapy, or radiation for this cancer before.
- You are generally in good health, with adequate heart, liver, kidney, and blood cell function.
- You have not had treatment with immunotherapy drugs (like PD-1/PD-L1 inhibitors) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy plus the immunotherapy drug toripalimab before surgery can improve outcomes for women with early-stage triple-negative breast cancer that tests positive for PD-L1.
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
This study compares a new drug (JS004) added to an immunotherapy and chemotherapy combination versus the usual immunotherapy plus chemotherapy or chemotherapy alone. It aims to see if adding this new drug can shrink breast cancer more effectively before surgery.
This trial tests whether adding sintilimab (an immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) to standard chemotherapy before surgery can improve outcomes for women with stage II or III triple-negative breast cancer. It may help your immune system fight the cancer more effectively.
This trial tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. The treatment is given before surgery to shrink the tumor and make surgery more effective.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.